Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jul 21, 2023 10:56am
130 Views
Post# 35551467

RE:RE:RE:RE:The issue of the safe use of higher doses of vaccinia virus

RE:RE:RE:RE:The issue of the safe use of higher doses of vaccinia virus July 21, 2023 - Turnstone Biologics closes $80 million IPO.

The San Diego-based company has already set how it plans to use the money to fund phase 1 work on its lead asset TIDAL-01 for breast and colorectal cancers as well as move another tumor-infiltrating lymphocyte into the clinic and run combination trials with viral immunotherapies.


In July 2022  Takeda walked away from the vaccinia virus cancer prospect it picked up in a $120 million deal from Turnstone Biologics in 2019 due to the explicitly referred to "safety signal" of the pathologic vaccina virus.

https://www.fiercebiotech.com/biotech/turnstone-turns-fortunes-around-80m-ipo-haul
<< Previous
Bullboard Posts
Next >>